Baricitinib

Base Information

Chemical Name:Baricitinib
CAS No.:1187594-09-7
Molecular Formula:C16H17N7O2S
Molecular Weight:371.423
Hs Code.:29350090
Mol file:1187594-09-7.mol

Synonyms:INCB 028050;LY 3009104;1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile;

Suppliers and Price of Baricitinib

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Baricitinib
1mg
$ 65.00

TRC
Baricitinib
5mg
$ 185.00

Tocris
Baricitinib ≥98%(HPLC)
50
$ 209.00

DC Chemicals
Baricitinib(INCB28050,LY3009104) >98%
1 g
$ 1200.00

DC Chemicals
Baricitinib(INCB28050,LY3009104) >98%
100 mg
$ 300.00

Crysdot
Baricitinib 98+%
100mg
$ 70.00

Crysdot
Baricitinib 98+%
50mg
$ 49.00

Crysdot
Baricitinib 98+%
25mg
$ 38.00

Crysdot
Baricitinib 98+%
250mg
$ 86.00

Crysdot
Baricitinib 98+%
1g
$ 162.00

Total 161 raw suppliers

Chemical Property of Baricitinib

Chemical Property:

PKA:11.66±0.50(Predicted)
PSA：128.94000
Density:1.6±0.1 g/cm³
LogP:2.11438
Storage Temp.:-20°C
Solubility.:Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).

Purity/Quality:

98% ^*data from raw suppliers

Baricitinib ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Description Baricitinib (1187594-09-7), approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50?= 5.9 nM) and 2 (5.7 nM), over 3 (0.56 μM).1?It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2?Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3
Uses Baricitinib is a JAK1 and JAK2 inhibitor and have been used as a promising treatment for rheumatoid arthritis.
Clinical Use Janus kinase inhibitor: Treatment of moderate to severe active rheumatoid arthritis
Drug interactions Potentially hazardous interactions with other drugs Avoid with other DMARDs due to increased immunosuppression. Use with care with other immunosuppressants. Antipsychotics: increased risk of agranulocytosis with clozapine - avoid. Live vaccines: avoid concomitant use

Technology Process of Baricitinib

There total 35 articles about Baricitinib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 99.0%

: 1919837-50-5
2-(1-(ethanesulfonyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-3-yl)acetonitrile

: 3680-69-1
4-chloro-1H-pyrrolo[2,3-d]pyrimidine

: 1187594-09-7
Baricitinib

Guidance literature:: With tetrakis(triphenylphosphine) palladium⁽⁰⁾; potassium carbonate; In 1,4-dioxane; water; at 80 - 85 ℃; for 5h;

Reference yield: 93.0%

: tert-butyl 4-{1-[3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl}-7H-pyrrolo[2.3-d]pyrimidine-7-carboxylate

: 1187594-09-7
Baricitinib

Guidance literature:: With hydrogenchloride; In ethanol; at 40 - 45 ℃;

Reference yield: 91.2%

: 1187595-85-2
2-[1-(ethanesulfonyl)azetidin-3-ylidene]acetonitrile

: C₁₄H₁₅N₅O₂

: 1187594-09-7
Baricitinib

Guidance literature:: C₁₄H₁₅N₅O₂; With potassium carbonate; In acetonitrile; at 20 ℃; for 0.5h;

2-[1-(ethanesulfonyl)azetidin-3-ylidene]acetonitrile; With 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetonitrile; at 40 ℃; for 8h;